

## **Annual General Meeting in Modus Therapeutics Holding AB (publ)**

**Today, the annual general meeting of 2023 was held in Modus Therapeutics Holding AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website [www.modustx.com](http://www.modustx.com)).**

Modus Therapeutics' Annual General Meeting on 11 May 2023 resolved in accordance with the following:

- That no dividend would be paid.
- To discharge the board members and the managing director from liability with respect to their management of the company for the financial year 2022.
- That the board of directors shall comprise three board members without any deputies.
- To re-elect the board members Viktor Drvota, Ellen Donnelly and Torsten Goesch and to re-elect Viktor Drovta as the chairman of the board.
- To re-elect Ernst & Young Aktiebolag as auditor.
- To adopt principles for the Nomination Committee, in accordance with the Nomination Committee's proposal.
- To authorize the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares, convertibles and/or warrants.
- To approve a bridge financing facility of up to SEK 7 million from Karolinska Development.

**For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

**Certified Adviser**

Svensk Kapitalmarknadsgranskning AB

Website: [www.skmg.se](http://www.skmg.se)

**About Modus Therapeutics and sevuparin**

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

**Attachments**

[Annual General Meeting in Modus Therapeutics Holding AB \(publ\)](#)